<code id='16C7996854'></code><style id='16C7996854'></style>
    • <acronym id='16C7996854'></acronym>
      <center id='16C7996854'><center id='16C7996854'><tfoot id='16C7996854'></tfoot></center><abbr id='16C7996854'><dir id='16C7996854'><tfoot id='16C7996854'></tfoot><noframes id='16C7996854'>

    • <optgroup id='16C7996854'><strike id='16C7996854'><sup id='16C7996854'></sup></strike><code id='16C7996854'></code></optgroup>
        1. <b id='16C7996854'><label id='16C7996854'><select id='16C7996854'><dt id='16C7996854'><span id='16C7996854'></span></dt></select></label></b><u id='16C7996854'></u>
          <i id='16C7996854'><strike id='16C7996854'><tt id='16C7996854'><pre id='16C7996854'></pre></tt></strike></i>

          fashion

          fashion

          author:comprehensive    Page View:4297
          George Yancopoulos on the 2024 Breakthrough Summit East stage.
          George Yancopoulos on the 2024 Breakthrough Summit East stage STAT

          George Yancopoulos is in touch with his teenage self.

          After 35 years as head scientist at Regeneron Pharmaceuticals, Yancopoulos has led the development of 12 approved medicines, turning a once-fledgling company into the $100 billion global drugmaker it is today. And you can trace a straight line back to the childhood fascination with science he fostered growing up in Woodside, Queens.

          advertisement

          “My high school science project was about regenerating neurons, and ‘Regeneron’ is a contraction of ‘regenerating neurons,’” Yancopoulos said at the STAT Summit East on Thursday. “In some ways I’m still working on my high school science project.”

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          How one medical school became remarkably diverse
          How one medical school became remarkably diverse

          ThefirstclassattheUniversityofCalifornia,Davismedicalschool,in1972,waspredominantlywhiteandmale.Chri

          read more
          Illumina to lay off 10% of research and development team
          Illumina to lay off 10% of research and development team

          AdobeSANDIEGO—Monthsafterannouncingplanstocutcostsby$100million,DNAsequencinggiantIlluminahasbegunto

          read more
          FDA approval of Sarepta Duchenne genetic therapy gives me hope
          FDA approval of Sarepta Duchenne genetic therapy gives me hope

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

          read more

          GOP inquiry over gain

          BernardMossCourtesyNIAIDFormorethanhalfacentury,scientistBernardMosshasbeencommandingtheattentionofp